Enliven Therapeutics, INC Form 4 insider transactions

Enliven Therapeutics' Chief Operating Officer, Anish Patel, sold 6,667 shares of common stock for approximately $20.10 per share as part of a pre-arranged trading plan.

Enliven Therapeutics CFO Benjamin Hohl exercised stock options and subsequently sold 3,250 shares of common stock under a pre-arranged 10b5-1 trading plan.

Enliven Therapeutics' Chief Scientific Officer, Joseph P. Lyssikatos, sold 4,000 shares of common stock for approximately $20.25 per share pursuant to a pre-arranged Rule 10b5-1 trading plan.

Enliven Therapeutics President and CEO Samuel Kintz sold 3,700 shares of common stock for $20.0615 per share, executed under a pre-arranged Rule 10b5-1 trading plan.

Enliven Therapeutics' Chief Scientific Officer, Joseph P Lyssikatos, sold 1,500 shares of common stock for $20.03 per share under a pre-arranged trading plan.

Enliven Therapeutics President and CEO Samuel Kintz sold 2,800 shares of common stock for $20.03 per share, executed under a pre-arranged 10b5-1 trading plan.

Enliven Therapeutics' Chief Scientific Officer, Joseph P. Lyssikatos, reported the sale of 7,000 shares of common stock through a pre-arranged trading plan.

Samuel Kintz, President and CEO of Enliven Therapeutics, sold 6,000 shares of common stock in September 2025 through a pre-arranged Rule 10b5-1 trading plan.

Enliven Therapeutics' Chief Operating Officer, Anish Patel, sold 6,667 shares of common stock for $20.2426 per share on September 8, 2025, under a pre-arranged trading plan.

Enliven Therapeutics CFO Benjamin Hohl exercised options and sold 3,250 shares of common stock for a significant gain under a pre-arranged 10b5-1 trading plan.

Enliven Therapeutics' President and CEO, Samuel Kintz, reported the sale of 1,517 common shares for approximately $20.00 per share, executed under a pre-arranged 10b5-1 trading plan.

Enliven Therapeutics' Chief Scientific Officer, Joseph P. Lyssikatos, sold 12,500 shares of common stock in August 2025 under a pre-arranged trading plan.

Enliven Therapeutics CEO Samuel Kintz sold common stock shares totaling $219,896 under a pre-arranged 10b5-1 trading plan.

Enliven Therapeutics' Chief Operating Officer, Anish Patel, sold 6,667 shares of common stock through a pre-arranged trading plan.

Enliven Therapeutics' Chief Financial Officer, Benjamin Hohl, executed a pre-planned exercise of stock options and subsequent sale of common stock totaling 3,250 shares under a Rule 10b5-1 trading plan.

Enliven Therapeutics' Chief Scientific Officer, Joseph P. Lyssikatos, sold 12,500 shares of common stock for approximately $278,000 through a pre-established Rule 10b5-1 trading plan.

Enliven Therapeutics, Inc. President and CEO, Samuel Kintz, reported the sale of 12,500 shares of common stock on July 17, 2025, through a pre-arranged Rule 10b5-1 trading plan.

Enliven Therapeutics' Chief Financial Officer, Benjamin Hohl, executed a pre-planned transaction involving the exercise of stock options and the subsequent sale of common stock on July 10, 2025.

Enliven Therapeutics' Chief Operating Officer, Anish Patel, reported planned sales of company common stock totaling 6,667 shares through a pre-arranged Rule 10b5-1 trading plan.

Enliven Therapeutics' Chief Financial Officer, Benjamin Hohl, completed an option exercise and subsequent sale of common stock on June 27, 2025, as part of a pre-arranged 10b5-1 trading plan.

Enliven Therapeutics' Chief Scientific Officer, Joseph P. Lyssikatos, sold 12,500 shares of common stock for approximately $21.3966 per share, as part of a pre-established Rule 10b5-1 trading plan.

Enliven Therapeutics, Inc. President and CEO Samuel Kintz executed the sale of 12,500 shares of common stock on June 17, 2025, as part of a pre-established Rule 10b5-1 trading plan.

Enliven Therapeutics, Inc. Chief Financial Officer Benjamin Hohl exercised stock options and subsequently sold 3,000 shares of common stock on June 13, 2025, as part of a pre-arranged Rule 10b5-1 trading plan.

Enliven Therapeutics' Chief Operating Officer, Anish Patel, sold 6,667 shares of common stock on June 9, 2025, through a pre-arranged Rule 10b5-1 trading plan.

Enliven Therapeutics' Chief Scientific Officer, Joseph P. Lyssikatos, sold 7,500 shares of common stock for approximately $20.03 per share as part of a pre-established Rule 10b5-1 trading plan.

Enliven Therapeutics, Inc. President and CEO, Samuel Kintz, reported the sale of 7,500 shares of common stock for approximately $20.05 per share, executed under a Rule 10b5-1 trading plan.

Enliven Therapeutics' Chief Financial Officer, Benjamin Hohl, exercised stock options and subsequently sold the acquired common stock on May 27, 2025, as part of a pre-established Rule 10b5-1 trading plan.

Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics, sold 5,000 shares of common stock at an average price of $16.3067 under a pre-arranged 10b5-1 trading plan.

Enliven Therapeutics CEO Samuel Kintz sold 5,000 shares of common stock at an average price of $16.4906, executed under a pre-arranged 10b5-1 trading plan.

Anish Patel, COO of Enliven Therapeutics, sold shares of common stock on May 7, 2025, under a pre-arranged Rule 10b5-1 trading plan.